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Takotsubo syndrome is an acute reversible heart failure syndrome that is increasingly recognized in modern cardiology practice. This Position
Statement from the European Society of Cardiology Heart Failure Association provides a comprehensive review of the various clinical
and pathophysiological facets of Takotsubo syndrome, including nomenclature, definition, and diagnosis, primary and secondary clinical
subtypes, anatomical variants, triggers, epidemiology, pathophysiology, clinical presentation, complications, prognosis, clinical investigations,
and treatment approaches. Novel structured approaches to diagnosis, risk stratification, and management are presented, with new algorithms
to aid decision-making by practising clinicians. These also cover more complex areas (e.g. uncertain diagnosis and delayed presentation) and
the management of complex cases with ongoing symptoms after recovery, recurrent episodes, or spontaneous presentation. The unmet
needs and future directions for research in this syndrome are also discussed.
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Executive summary
• Nomenclature: ‘Takotsubo syndrome’ is recommended as the
formal name for this condition, and the term cardiomyopathy
is avoided.
*Corresponding author: NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Tel +44 207 352 8121, Fax +44 207
351 8776, Email: a.lyon@ic.ac.uk
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.. • Diagnosis: a new set of seven diagnostic criteria is pro-
posed incorporating anatomical features, ECG changes, car-
diac biomarkers, and reversibility of the myocardial dysfunction
(Box 1; Diagnostic algorithm).
• Clinical subtypes: classification as ‘primary’ or ‘secondary’ Takot-
subo syndrome, depending on clinical context and presence of
© 2015 The Authors
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Takotsubo Syndrome Diagnostic Algorithm
a major medical, surgical, obstetric, or psychiatric emergency
triggering the Takotsubo syndrome episode.
• Triggers: a stressful trigger is typical but not always present.
Triggers can be emotional or physical, including acute medical,
surgical, obstetric, or psychiatric emergencies (Table 1).
• Anatomical variants: three common and several rare anatomical
variants are currently recognized (Table 2). .
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.. • Epidemiology: Takotsubo syndrome is increasingly recognized
and reported, and many features suggest a different pathophys-
iological condition from coronary atherosclerosis. Takotsubo
syndrome appears to be more common than previously recog-
nized, but the precise incidence is not known.
• Complications: cardiac and non-cardiac complications are com-
mon during the acute episode (Table 3).
© 2015 The Authors
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Takotsubo Syndrome Management Algorithm
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Box 1 Heart Failure Association diagnostic criteria for Takotsubo
syndrome
1. Transient regional wall motion abnormalities of LV or RV myocardium which are frequently, but not always, preceded by a
stressful trigger (emotional or physical).
2. The regional wall motion abnormalities usuallya extend beyond a single epicardial vascular distribution, and often result in
circumferential dysfunction of the ventricular segments involved.
3. The absence of culprit atherosclerotic coronary artery disease including acute plaque rupture, thrombus formation, and
coronary dissection or other pathological conditions to explain the pattern of temporary LV dysfunction observed (e.g.
hypertrophic cardiomyopathy, viral myocarditis).
4. New and reversible electrocardiography (ECG) abnormalities (ST-segment elevation, ST depression, LBBBb, T-wave inversion,
and/or QTc prolongation) during the acute phase (3 months).
5. Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during the acute phase.
6. Positive but relatively small elevation in cardiac troponin measured with a conventional assay (i.e. disparity between the
troponin level and the amount of dysfunctional myocardium present).c
7. Recovery of ventricular systolic function on cardiac imaging at follow-up (3–6 months).d
aAcute, reversible dysfunction of a single coronary territory has been reported.
bLeft bundle branch block may be permanent after Takotsubo syndrome, but should also alert clinicians to exclude other cardiomy-
opathies. T-wave changes and QTc prolongation may take many weeks to months to normalize after recovery of LV function.
cTroponin-negative cases have been reported, but are atypical.
dSmall apical infarcts have been reported. Bystander subendocardial infarcts have been reported, involving a small proportion of the
acutely dysfunctional myocardium. These infarcts are insufficient to explain the acute regional wall motion abnormality observed.
• Risk stratification: after confirmed or suspected diagnosis of
Takotsubo syndrome, risk stratification is recommended to
guide treatment (Management algorithm; Box 4).
• Treatment: a new management algorithm is proposed, based
on risk stratification into higher risk and lower risk pathways
(Management algorithm).
• Recurrence: management of recurrent Takotsubo syndrome and
the role of prophylactic treatment are discussed. Currently
no evidence supports prophylactic treatment after the first
presentation.
Introduction
Takotsubo syndrome is an acute and usually reversible heart failure
syndrome first described in 1990 which is increasingly recognized
with access to urgent coronary angiography for patients with
acute ‘cardiac’ chest pain.1 Since the initial description, the clinical
community has increasingly recognized that this syndrome is dis-
tinct from acute coronary syndrome (ACS), although the initial pre-
sentation has similar features to ST-segment elevation myocardial
infarction (STEMI) or non-ST-segment elevation myocardial infarc-
tion (NSTEMI).2–10 Early access to diagnostic coronary angiog-
raphy has helped identify this condition, and the number of case
reports, series, and registries reported has increased over the last
25 years, offering different insights into this syndrome.11
To date there have been no randomized trials to define the opti-
mal management of patients with suspected Takotsubo syndrome,
with respect to both diagnosis and treatment. The increasing vari-
ety of clinical contexts in which this syndrome has been described .
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. implies that multiple pathophysiological processes may converge to
generate a similar clinical phenotype. As a result, clinical decisions
are challenging, and many patients currently receive a ‘default’ ACS
management strategy.
The published literature on Takotsubo syndrome and related
stress-induced cardiac syndromes consists of case reports, case
series, observational cohorts from screening discharge coding
across healthcare networks, and data collected from national
Takotsubo syndrome registries. These registries vary in size but
are generally considered small by contemporary standards (<600
patients). This current published information is level of evidence
C for conventional clinical guidelines. This document is a Position
Statement and not a guideline; current evidence was reviewed
by a group of experts with a specialist interest in Takotsubo syn-
drome who provided their opinion and consensus of the current
best practice for the diagnosis and management of patients with
Takotsubo syndrome.
Nomenclature
Various names have been used to describe the acute appear-
ance now classically described as a ‘Takotsubo cardiomyopathy’
or ‘Takotsubo syndrome’, following the initial label given by Sato
and colleagues in 1990 and 1991, which reflects the resem-
blance of the left ventricle at end-systole to the octopus pots of
Japanese fisherman in the Hiroshima fish markets.12 Many alter-
natives names have been used, including stress or stress-induced
cardiomyopathy,13 apical ballooning syndrome,3 ampullary-shaped
© 2015 The Authors
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Table 1 Triggers for secondary Takotsubo syndrome
Endocrine
e.g. Phaeochromocytoma, thyrotoxicosis (endogenous and iatrogenic), SIADH, Addisonian crisis, multiple endocrine neoplasia 2A syndrome,
hyperglycaemic hyperosmolar state, hyponatraemia, severe hypothyroidism, Addison’s disease, adrenocorticotropin hormone deficiency,
autoimmune polyendocrine syndrome II
Neurological and neurosurgical
Acute neurosurgical emergencies (e.g. subarachnoid haemorrhage, acute head injury, acute spinal injury)
Acute neuromuscular crises, especially if involving acute ventilatory failure (e.g. acute myasthenia gravis, acute Guillain–Barré syndrome)
Epileptic seizures, limbic encephalitis, ischaemic stroke, posterior reversible encephalopathy syndrome
Respiratory
Acute exacerbation of asthma or COPD (especially with excessive use of inhaled beta2-agonists)
Acute pulmonary embolism
Acute pneumothorax
Obstetric, e.g. miscarriage, labour, emergency Caesarean section
Psychiatric
Acute anxiety attack/panic disorder
Attempted suicide
Drug-withdrawal syndromes
Electroconvulsive therapy
Gastrointestinal, e.g. acute cholecystitis, biliary colic, acute pancreatitis, severe vomiting, severe diarrhoea, pseudomembranous colitis,
peritonitis
Infection
Severe sepsis
Babesiosis
Cardiological
Dobutamine stress echocardiography
Radiofrequency arrhythmia ablation
Pacemaker implantation
Electrical DC cardioversion for atrial fibrillation
Post-cardiac arrest including ventricular fibrillation
Haematological
Blood transfusions
Thrombotic thrombocytopenic purpura
Surgical
Many cases have been reported during induction of general anaesthesia or during non-cardiac surgery or interventional procedures under
local or general anaesthesia (e.g. cholecystectomy, hysterectomy, rhinoplasty, Caesarean section, radiofrequency liver ablation,
radiotherapy, colonoscopy, difficult urinary catheterization, carotid endarterectomy)
Medication and illicit drugs
Epinephrine injection
Nortriptyline overdose, venlafaxine overdose, albuterol, flecanide, metoprolol withdrawal, 5-fluorouracil, duloxetine
Cocaine abuse
SIADH, syndrome of inappropriate antidiuretic hormone secretion.
cardiomyopathy,14,15 and ‘broken heart syndrome’ in the context
of bereavement.16
The authors suggest ‘Takotsubo syndrome’ as a unifying term
for this clinical entity. ‘Takotsubo’ has now become engrained
in both medical literature and teaching, and several Takotsubo
registries have been established.17–21 Since the diagnosis is cur-
rently based on a series of clinical observations (see below),
there is consensus that it fulfils the definition of a clinical syn-
drome. The term ‘cardiomyopathy’ implies a primary disease of
the cardiac muscle and in clinical cardiology is usually applied to
a primary heart muscle disorder of genetic or unknown origin.
Patients with Takotsubo syndrome do not appear to have a pri-
mary muscle disorder, and no common genetic basis has been .
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.. identified. The full recovery of patients and the low rate of major
adverse cardiac events at follow-up in reported series strongly
suggest that Takotsubo syndrome is different from the primary
cardiomyopathies.
Definition
Takotsubo syndrome and associated variants are a form of acute
and usually reversible heart failure syndrome. It may be a form of
acute catecholaminergic myocardial stunning, as there is no occlu-
sive CAD to explain the pattern of temporary LV dysfunction
observed. Patients with Takotsubo syndrome have typical features
that must be identified to confirm the diagnosis. Several previous
© 2015 The Authors
European Journal of Heart Failure © 2015 European Society of Cardiology
Current state of knowledge on Takotsubo syndrome 13
Table 2 Anatomical variants of Takotsubo syndrome
Variant Estimated prevalence
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Apical with or without MLV variant
(typical)
75–80%
MLV ∼10–15%
Inverted or basal ∼5%
Biventricular Clinical <0.5%; CMR 33%
Right ventricular Unknown
Apical tip sparing Unknown
Possible atypical variants
Global Unknown
Focal Unknown
CMR, cardiac magnetic resonance; MLV, mid-left ventricular;
Table 3 In-hospital and long-term outcome of
Takotsubo syndrome
Complication/outcome Frequency
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acute complications
Right ventricular involvement 18–34%
Acute heart failure 12–45%
LV outflow tract obstruction 10–25%
Mitral regurgitation 14–25%
Cardiogenic shock 6–20%
Arrhythmias
Atrial fibrillation 5–15%
Ventricular arrhythmias 4–9%
Bradycardia, asystole 2–5%
Thrombus formation 2–8%
Pericardial tamponade <1%
Ventricular wall rupture <1%
In-hospital mortality 1–4.5%
Recurrence 5–22%
5-year mortality 3–17%
diagnostic criteria have been proposed, including those by the
Mayo Clinic (modified in 2008), the Japanese Takotsubo Cardiomy-
opathy Group, the Gothenburg Group, and the Takotsubo Italian
Network.4,20,22–24
We have reviewed, adapted, and amended these criteria to
generate the new 2015 Heart Failure Association of the Euro-
pean Society of Cardiology (HFA) Takotsubo Syndrome Diagnos-
tic Criteria (Box 1). Although this condition predominantly affects
post-menopausal women (∼90% of all cases reported, particularly
in larger cohorts), men and younger women can have this condi-
tion. Therefore, these demographic features are not a mandatory
part of the proposed diagnostic criteria. Takotsubo syndrome is
reversible—a critical feature that helps to differentiate it from
many other acute heart failure syndromes. Timelines of recovery
vary depending on the severity of the acute episode. As a guide,
LVEF usually recovers by 12 weeks, but ECG changes and BNP
levels may take 6–12 months to recover and, in some cases, can
remain permanently abnormal, e.g. if myocardial scarring occurs. ..
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.. Distinguishing Takotsubo syndrome from acute infective
myocarditis can be challenging if there is evidence of acute
myocardial oedema and inflammation in a typical anatomical
distribution, as is common during the acute episode of Takotsubo
syndrome (Box 2).25–27 This could be considered a form of acute
catecholaminergic myocarditis, given the appearance on T2-STIR
cardiac magnetic resonance (CMR) and the rise in cardiac tro-
ponin. A careful history and other clinical features can normally
differentiate these conditions (e.g. the stressful trigger, if present,
in Takotsubo syndrome vs. the viral prodromal illness with fever
in acute infective myocarditis).28
Another difference from the modified Mayo diagnostic crite-
ria is the inclusion of phaeochromocytoma. In patients with this
condition, and particularly those with an epinephrine-secreting
phaeochromocytoma, acute Takotsubo syndrome may result from
a catecholamine storm, in an analogous manner to a catecholamine
storm after a sudden stressful experience.29–34 The pathophys-
iology and clinical phenotype are identical, and therefore the
consensus of the authors was to include patients with phaeochro-
mocytoma but to consider them as cases of secondary Takotsubo
syndrome (Table 1).
Clinical subtypes: primary
and secondary Takotsubo
syndrome
Takotsubo syndrome comes to the attention of medical personnel
in a variety of clinical scenarios and contexts. Cases can be classified
as either primary or secondary Takotsubo syndrome.
Primary Takotsubo syndrome
In primary Takotsubo syndrome, the acute cardiac symptoms are
the primary reason for seeking care, usually from emergency med-
ical services, acute cardiac services, or the primary care physician.
Such patients may or may not have clearly identifiable stressful
triggers (often emotional). Potential co-existing medical conditions
may be the predisposing risk factors but are not the primary cause
of the catecholamine rise. These cases can be considered primary
Takotsubo syndrome, and their clinical management depends on
the specific complications.
Secondary Takotsubo syndrome
A substantial proportion of cases occur in patients already hos-
pitalized for another medical, surgical, anaesthetic, obstetric, or
psychiatric condition. In these patients, sudden activation of the
sympathetic nervous system or a rise in catecholamines precipi-
tates an acute Takotsubo syndrome as a complication of the pri-
mary condition or its treatment. We propose that such cases
be diagnosed as secondary Takotsubo syndrome. Their manage-
ment should focus not only on the Takotsubo syndrome and its
cardiac complications but also on the condition that triggered the
syndrome. Examples of medical conditions reported to trigger
secondary Takotsubo syndrome are listed in Table 1.
© 2015 The Authors
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Box 2 Differences between Takotsubo syndrome and acute
myocarditis
Category Takotsubo syndrome Acute myocarditis
Gender and age 90% female. Majority >50 years and
post-menopausal.
No sex prevalence. More frequent in the young.
Preceding events Stressor trigger identifiable in ∼70% of
cases.
Symptoms and signs of infection often present (fever,
chills, headache, muscle aches, general malaise, cough,
nausea, vomiting, diarrhoea).
Cardiac symptoms Chest pain, dyspnoea, palpitations. Chest pain, dyspnoea, peripheral oedema, fatigue, and
palpitations.
Clinical signs Pericardial rub rare. Pericardial rub may be present.
ECG at admission ST changes such as ST-segment elevation
or non ST-segment elevation. Deep T
wave inversion. QT prolongation. Rarely
normal.
ST-segment elevation or depression, negative T-wave,
bundle branch block, atrioventricular block, low voltage,
and/or ventricular arrhythmias. Normal in several cases.
Cardiac enzymes Low/moderate troponin rise. Discrepancy
between the large amount of
dysfunctional myocardium and peak
troponin level.
Frequently significant troponin rise, proportional to the
hypokinetic area. Normal in several cases.
Other biomarkers C-reactive protein (CRP) mildly elevated
unless infective trigger. BNP moderately
or significantly elevated.
Erythrocyte sedimentation rate and CRP elevated. BNP
basically elevated. Acute viral serology may be detected.
Echocardiography Apical ballooning, anatomical variants,
‘circumferential pattern’, left ventricular
outflow tract obstruction (LVOTO),
right ventricular (RV) involvement,
transient mitral regurgitation.
Localized or diffuse wall motion abnormalities of LV
and/or RV dilatation, increased wall thickness,
pericardial effusion.
Cardiac magnetic
resonance imaging
High T2 signal intensity (oedema), late
gadolinium enhancement (LGE) usually
absent acutely. If present acutely patchy
LGE which usually resolves at follow-up.
Absence of typical infarct LGE pattern.
High T2 signal intensity (oedema), LGE with
non-ischaemic distribution (often epicardial). Absence
of typical infarct LGE pattern.
Histological findings Contraction band necrosis. Infiltration of many inflammatory cells. Interstitial oedema.
Viral genome, separation
of virus, or
identification of virus
by antibody titre
Rare and usually absent where measured. Often positive.
Prognosis 50% of cases have acute complications,
4–5% mortality.
Variable but majority full recovery. Highest mortality with
fulminant myocarditis.
Therapy Supportive. Supportive. Immunosuppression in severe cases if giant
cell myocarditis suspected.
Anatomical variants
Primary and secondary Takotsubo syndromes encompass an array
of anatomical variants (Table 2; Figure 1).35–37 The initial report
of Takotsubo syndrome described what is now considered the
classical pattern: LV regional wall motion abnormality (RWMA)
with apical and circumferential mid-ventricular hypokinesia and
basal hypercontractility. At end-systole, the left ventricle typically
resembles the ‘Takotsubo’ with a narrow neck and globular lower
portion, giving the appearance of virtual apical ballooning. This .
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..
. typical variant with apical dysfunction is present in ∼50–80% cases,
depending on the series.
Two other variants are common: the inverted Takotsubo or
basal variant, with circumferential basal hypokinesia and apical
hypercontractility, also referred to as the ‘nutmeg’ or ‘artichoke’
heart; and the mid left ventricular (MLV) variant, with circum-
ferential mid-ventricular hypokinesia and both basal and apical
hypercontractility.38–40 The end-systolic appearance of the MLV
variant has been likened to a Greek vase or the ace of spades; how-
ever, the basal variant can also resemble the ace of spades (Figure 1).
© 2015 The Authors
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Figure 1 Anatomical variants of Takotsubo syndrome. (A) Ventriculographic appearances showing paired end-diastolic image (above) and
end-systolic image (below) of a mid-ventricular variant (A and B), an inverted Takotsubo variant (C and D), and a typical apical Takotsubo
variant (E and F). Adapted from Haghi et al.138 (B) Cardiac magnetic resonance (CMR) appearances showing paired acute end-diastolic (left),
acute end-systolic (centre), and follow-up end-systolic (right) images for typical apical Takotsubo syndrome (top row), mid-ventricular variant
(middle row), and inverted Takotsubo variant (lower row) (reproduced from Eitel et al.35). (C) Biventricular involvement with LV and RV apical
hypokinesia. White arrows highlight regions of hypokinesia in the end-systolic four-chamber view (adapted from Haghi et al.36).
© 2015 The Authors
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In both of these variants, reversible LV dysfunction affects more
than one coronary territory, usually in a circumferential pattern,
in the absence of culprit CAD. Rarer variants include biventricu-
lar apical dysfunction, dysfunction sparing the apical tip (possibly a
form of MLV Takotsubo), and isolated right ventricular (RV) Takot-
subo syndrome.36,41–43
The affected LV segments may recover at different rates, a pos-
sible explanation for the various anatomical variants observed.
Intriguingly, Takotsubo syndrome may recur as a different anatom-
ical variant in the same patient, suggesting that a person can be
susceptible to more than one subtype.44,45
Epidemiology
Several series of Asian and Western (predominantly Caucasian)
populations suggest that 1–2% of patients with suspected ACS
are eventually diagnosed with Takotsubo syndrome.7,37 In those
series, the incidence of Takotsubo syndrome was probably under-
estimated. The possibility of pre-hospital sudden cardiac death
from Takotsubo syndrome was not considered and, with increasing
awareness and more widespread access to early coronary angiog-
raphy, Takotsubo syndrome is now recognized more frequently.
The largest reported cohorts are from the Nationwide Inpatient
Sample (NIS-USA). However, these reports were based on ICD-10
(International Disease Classification 10th Revision) discharge cod-
ing, with no uniform system for ensuring correct diagnosis or esti-
mating the number of cases missed. This registry represents ∼20%
of all US non-federal community hospitals. The first NIS-USA study
reported data on 6837 patients with Takotsubo syndrome from
2008.46 The second NIS-USA study reported data from 24 701
patients from 2008–2009; it appears to be a 24-month data set,
but may include patients in the first study.47 These numbers imply
that there are ∼50 000–100 000 cases per annum in the USA, with
similar estimated numbers in Europe.
In the first study, Takotsubo syndrome was diagnosed in 0.02%
of all acute hospitalizations (6837/33 506 402 patients).46 The
majority (90%) were elderly post-menopausal women (66–80
years of age), a demographic repeated across many published
cohorts. The risk factors included smoking, alcohol abuse, anxiety
states, and hyperlipidaemia. The second study, and largest cohort
to date, reported details of 24 701 patients with a discharge
code for Takotsubo syndrome. The demographics were similar
to those in the first study: 89% were women, the mean age was
66.9± 30.7 years, and most patients (59.6%) were ≥65 years old.47
Gender differences
Takotsubo syndrome occurs predominantly in post-menopausal
women. The German Takotsubo syndrome registry includes 324
patients; 91% are female (mean age 68± 12 years) and 9% are male
(mean age 66± 12 years). The demographic and clinical charac-
teristics were similar in men and women.17 However, emotional
stress or the absence of identifiable triggers was more common
in women. Conversely, a physical stressful triggering event, shock,
or resuscitation on presentation was more common in men, who
also had higher levels of cardiac biomarkers (troponin). In the larger ..
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.. of the two NIS-USA cohorts, the mortality rate was higher in men
(8.4% vs. 3.6%, P< 0.0001), perhaps reflecting the higher frequency
of underlying severe critical illness and secondary Takotsubo syn-
drome (36.6% in men vs. 26.8% in women, P< 0.0001).47
Age
Elderly patients are considered to be at higher risk of Takotsubo
syndrome and related major complications, and <10% of patients
are below 50 years of age.46,48 In the Takotsubo Italian Network,
Takotsubo syndrome patients older than 65 years have a greater
prevalence of hypertension and cerebrovascular disease, a lower
glomerular filtration rate, and a lower LVEF at discharge compared
with younger patients. Older adults (≥75 years) have higher rates
of in-hospital complications and in-hospital mortality (6.3% vs. 2.8%
overall in-hospital mortality).18
Pathophysiology
The pathophysiology of Takotsubo syndrome is complex and
reflects the integrated and systemic physiological responses to
acute, severe stress and the cardiovascular responses to sud-
den surges in endogenous or exogenously administered cate-
cholamines. The pathophysiology has been extensively reviewed
elsewhere.10,49–52
Catecholamines appear to have a central role in the patho-
physiology of Takotsubo syndrome, as the trigger is often a sud-
den, unexpected stress; signs of sympathetic activation are present
at presentation, and secondary medical triggers can also lead to
extreme sympathetic activation. There are two initial elements of
the physiology to consider. The first is the cognitive centres of
the brain and hypothalamic–pituitary–adrenal (HPA) axis, and how
much epinephrine and norepinephrine are released in response to
a given stress (i.e. the ‘gain’ of the HPA axis). The second is the
response of the cardiovascular system (including the myocardium,
coronary arteries, and peripheral vasculature) and the sympathetic
nervous system to the sudden sympathetic activation and surge in
circulating catecholamines.
Serum catecholamine levels at presentation are significantly
higher than resting levels in the same patient or in comparable
patients with acute heart failure due to acute myocardial infarction
(MI), suggesting the potential for excessive HPA gain and
epinephrine release.53 Iatrogenic Takotsubo syndrome has been
reported after administration of sympathomimetic drugs (e.g.
dobutamine in stress echocardiography).54
Several hypotheses have been proposed to explain the unique
cardiac appearance in Takotsubo syndrome and the cardiac
response to severe stress. These hypotheses can be broadly
divided into vascular and myocardial causes (Box 3) and may not be
mutually exclusive, as the entire cardiovascular system is exposed
to the same catecholamine storm. Many of these hypotheses are
still being investigated, as there is no current proven pathophysio-
logical mechanism to explain Takotsubo syndrome. There may be a
synergistic combination of more than one factor, and mechanistic
studies have yielded conflicting results.
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Box 3 Summary of
pathophysiological hypotheses
Vascular Acute multivessel coronary spasm.
Aborted myocardial infarction with
spontaneous recanalization.
Acute increased ventricular afterload.
Myocardial Acute left ventricular outflow tract
obstruction.
Direct catecholamine-mediated
myocardial stunning.
Vascular and
myocardial
Integrated cardiovascular physiology (a
cardio-circulatory syndrome).
Genetic susceptibility
The stressful trigger implies that the pathophysiology of Takot-
subo syndrome has a strong environmental component. However,
it is conceivable that some people have a genetic predisposition to
stress-induced Takotsubo syndrome. Although the syndrome is not
considered a primary genetic cardiomyopathy, a number of stud-
ies have explored the possibility of genetic risk factors. A genetic
predisposition has been suggested based on the few familial Takot-
subo syndrome cases described.55–58 Conflicting results have been
published regarding the presence or absence of functional poly-
morphisms in relevant candidate genes, such as 𝛼1-, 𝛽1-, and
𝛽2-adrenergic receptors, GRK5, and oestrogen receptors. These
studies had relatively small numbers of subjects. Resolving these
conflicts will require high-quality phenotyping, identification of can-
didate genes, and sharing of high-number/high-quality data in a
Takotsubo syndrome network.
Clinical presentation
and diagnosis
The typical patient with primary Takotsubo syndrome is a
post-menopausal women who has experienced severe, unexpected
emotional or physical stress.4 This may be unheralded or on the
background of elevated levels of stress or anxiety, including in
some cases a formal diagnosis of anxiety or panic disorder.46,59
However, most patients do not have prior history of stress-related
psychological conditions. Nevertheless, it is important to remem-
ber that 10% of cases in the largest reported series (NIS-USA)
were men or younger women, and 30–35% of cohort series
report classical cases in patients with no identifiable stressful
trigger.46 Thus, gender, menopausal status, and stressful triggers
are not mandatory features and are not included in our HFA
diagnostic criteria.
Patients with Takotsubo syndrome typically present with acute
chest pain of cardiac origin (angina), breathlessness, and palpi-
tations due to sinus tachycardia or arrhythmia; in more severe
cases, pre-syncope or syncope due to ventricular tachyarrhyth-
mias, severe left ventricular outflow tract obstruction (LVOTO), or ..
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.. cardiogenic shock may be present. Patients may describe a wave
of pressure from the chest to the neck and into the head, con-
sistent with the acute catecholamine and hypertensive surge and
frequently associated with diaphoresis and heightened anxiety.
Such patients should prompt urgent clinical evaluation and rapid
acquisition of a resting 12-lead ECG. These findings should activate
an ACS treatment pathway according to the ESC guidelines and,
where appropriate, urgent coronary angiography60 (see Diagnostic
algorithm). Coronary computed tomography angiography (CCTA)
may be considered in stable cases, particularly if the patient is
pain free and cardiac imaging (e.g. echocardiography) shows typical
features of Takotsubo syndrome.61
Once the diagnosis of Takotsubo syndrome is suspected in the
catheterization laboratory, early cardiac imaging and assessment
of cardiac biomarkers can help exclude MI and further stratify
risk. Given the spectrum of clinical and anatomical patterns, the
presence or absence of stressful triggers, and the potential pres-
ence of CAD or prodromal viral illnesses, borderline cases exist
(see Diagnostic algorithm). In such cases, CMR imaging with late
gadolinium enhancement (LGE) may be helpful.35,36 CMR is also
complementary to echocardiography to detect complications and
aid risk stratification, and has better sensitivity for detecting LV
apical thrombus.
Secondary Takotsubo syndrome
in specific clinical settings
Takotsubo syndrome can complicate a wide variety of acute
medical and surgical conditions, including elective non-cardiac
procedures (see ‘Secondary Takostubo syndrome’ and Table 1).
Iatrogenic causes during catecholamine administration (e.g. dobu-
tamine stress echocardiography) have also been reported. There-
fore, clinicians should be alert to Takotsubo syndrome in numerous
clinical settings, including the acute medical unit, endocrinol-
ogy ward, neurology ward, anaesthetic room, intensive care
units (including the neuro-intensive care unit), obstetric unit, and
psychiatric ward.
Takotsubo syndrome can be fatal because of mechanisms dis-
cussed below (see ‘Complications and acute prognosis’). Many
of these complications can be readily detected post-mortem in
a confirmed case of Takotsubo syndrome. More difficult is the
case of sudden non-hospital cardiac death in a patients with a
stressful precipitant and a structurally normal heart and coronary
arteries.62 These cases may have medico-legal or criminal implica-
tions, for example where sudden death occurs during restraint in
police custody or in the psychiatric department. A more precise
set of histopathological criteria is needed to help in post-mortem
evaluation and diagnosis of Takotsubo syndrome as a cause of
stress-induced sudden death.
Diagnostic investigations
Biomarkers
Cardiac troponin measured by conventional assays (not high sen-
sitivity) is elevated in >90% of patients with Takotsubo syndrome.
© 2015 The Authors
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However, the rise in serum troponin or creatinine kinase is dis-
proportionately low relative to the extent of RWMA and car-
diac dysfunction (i.e. widespread segmental akinesia/hypokinesia
of >5 segments and frequently >9 segments in the 17-segment
model).48
During the acute phase of Takotsubo syndrome, serum car-
diac natriuretic peptides (BNP or NT-proBNP) are almost
always elevated, frequently to extremely high levels that corre-
late more closely with the degree of ventricular wall motion
abnormality.63–66 The limited evidence to date suggests that BNP
and NT-proBNP are more useful diagnostic biomarkers than
troponin, and it is recommended that they be measured in all
suspected cases if the assay is available. Since normal levels are
extremely rare in Takotsubo syndrome, an elevated natriuretic
peptide level is included in the new diagnostic criteria (Box 1).
NT-proBNP is a valuable marker of myocardial deterioration and
recovery. Low NT-proBNP at admission may reliably indicate a
favourable prognosis and hence is included in our proposed risk
stratification criteria (Box 4).
Other biomarkers have been reported in research studies
but are not currently recommended in routine practice. Serum
catecholamines (epinephrine, norepinephrine, and dopamine),
neuropeptide-Y, and serotonin are typically elevated in Takotsubo
syndrome.53 Catecholamine levels are two to three times higher
in patients with Takotsubo syndrome than in those with acute
MI (Killip class III) at admission. This finding was reinforced by
another study, although not all patients presented with elevated
serum catecholamines.5,67 In a recent study, the profile of circu-
lating microRNAs (small non-coding RNA sequences) differed in
Takotsubo syndrome and STEMI patients,68 supporting a different
pathophysiology and the potential for developing future diagnostic
biomarkers.
Electrocardiography
Abnormalities on ECG are present in >95% of Takotsubo syn-
drome patients during the acute phase.7,48,69–71 Daily ECGs are
helpful, as a typical evolution has now been defined, and the poten-
tial for worsening of the QT interval is important in risk stratifica-
tion and may help distinguish Takotsubo syndrome from STEMI.72
However ECG criteria alone are not sufficient to differentiate
Takotsubo syndrome from STEMI.73
The ECG abnormalities during the acute phase (<12 h) are
ST-segment elevation, ST-segment depression, new LBBB, and
sometimes Q-waves, with deep and widespread T-wave inversion
and significant QT prolongation developing 24–48 h after the onset
of symptoms or the precipitating stressful trigger (when present).70
If presentation is delayed, T-wave inversion and QTc prolongation
without ST segment elevation might be observed. The QTc pro-
longation is often pronounced (>500ms), predisposing to torsades
de pointes and ventricular fibrillation.17,70 Significant QTc prolon-
gation is seldom seen in STEMI caused by coronary occlusion and
may help to differentiate the two conditions retrospectively; how-
ever, it should not be used for prospective diagnosis. A minority of
Takotsubo syndrome patients may present with a normal ECG, but
this is atypical. ..
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Box 4 Heart Failure Association
risk stratification in Takotsubo
syndrome
Risk factor Higher risk Lower risk
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MAJOR RISK FACTORS
Age ≥75 years See minor risk
factorsa
Systolic BP <110 mmHg ≥110 mmHg
Clinical pulmonary
oedemab
Present Absent
Unexplained
syncope, VT or VF
Present Absent
LVEF <35% See minor risk
factorsa
LVOTO ≥40 mmHg Absent or <40
mmHg
Mitral regurgitationc Present Absent
Apical thrombus Present Absent
New VSD or
contained
Present Absent
LV wall rupture
MINOR RISK FACTORS
Age 70–75 years <70 years
ECG
QTc ≥500 ms <500 ms
Pathological Q
waves
Present Absent
Persistent ST
elevationd
Present Absent
LVEF 35–45% ≥45%
Physical stressor Present Absent
Natriuretic peptides
BNP ≥600 pg/mL <600 pg/mL
NT-proBNP ≥2000 pg/mL NT-proBNP
<2000 pg/mL
Bystander
obstructive CAD
Present Absent
Biventricular
involvement
Present Absent
BP, blood pressure; LVOTO, left ventricular outflow tract
obstruction; VF, ventricular fibrillation; VSD, ventricular septal
defect; VT, ventricular tachycardia.
aSee minor criteria regarding LVEF in the absence of major
criteria.
bLower zone (basal) pulmonary rales on clinical examination
or evidence on chest X-ray.
cModerate or severe mitral regurgitation.
d≥3 days.
© 2015 The Authors
European Journal of Heart Failure © 2015 European Society of Cardiology
Current state of knowledge on Takotsubo syndrome 19
Coronary angiography and left
ventriculography
Most Takotsubo syndrome patients should have urgent coronary
angiography to exclude STEMI or NSTEMI because they present
with cardiac chest pain and have ST elevation or other changes
that could be interpreted as an ACS. In Takotsubo syndrome, the
epicardial coronary arteries are typically normal and unobstructed;
however, given the predilection for older patients, bystander CAD
can be present. If so, it is important to consider whether the CAD
is sufficient to cause the degree or pattern of LV dysfunction.
Several studies reviewing cohorts of Takotsubo syndrome patients
report bystander CAD in up to 10% of cases.74,75 Although not
causative, bystander CAD is a risk factor for more severe heart
failure during the acute episode (Box 4). Intravascular ultrasound
studies have demonstrated that plaque rupture or intracoro-
nary thrombosis is not present in Takotsubo syndrome.76 Once
causative coronary occlusion, including acute plaque rupture,
thrombus formation, and coronary dissection, has been excluded,
ventriculography should be performed unless there is a con-
traindication, since ventriculography will frequently be diagnostic
for Takotsubo syndrome. This is important as the wall motion
abnormalities may recover in hours and may be missed if imaging
is delayed. The typical pattern of wall motion abnormality is the
apical and mid-wall hypokinesis that earned this condition its
original ‘Takotsubo’ label. However, other anatomical variants may
occur (see ‘Anatomical variants’; Figure 1; Table 2).
Echocardiography
Transthoracic echocardiography with colour and tissue Doppler
should be the first non-invasive imaging technique to verify
a suspected diagnosis of Takotsubo syndrome. Transthoracic
echocardiography can assess LV morphology and function, iden-
tify anatomic variants, detect potential complications (e.g. LVOTO,
mitral regurgitation, RV involvement, thrombus formation, and
cardiac rupture), and monitor recovery.77–79 Key echocardio-
graphic features during the acute phase consist of a large area
of dysfunctional myocardium extending beyond the territory of a
single coronary artery and usually characterized by symmetrical
regional abnormalities involving the mid-ventricular segments of
the anterior, inferior, and lateral walls (a circumferential pattern).77
Among 227 patients enrolled in the Takotsubo Italian Network,
low LVEF, elevated E/e’ ratio, reversible moderate-to-severe mitral
regurgitation, and age ≥75 years correlated independently with
major adverse events (acute heart failure, cardiogenic shock, and
in-hospital death).80
Cardiac magnetic resonance
Cardiac magnetic resonance provides 3D anatomical information
that can distinguish Takotsubo syndrome from other cardiac dis-
eases and can help to elucidate its cause and pathophysiology.35 It
can accurately assess both LV and RV regional function and demon-
strate the typical patterns of RWMA (Figure 1; Table 2). Takotsubo
syndrome involves the right ventricle in up to one-third of patients, ..
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.. and CMR often provides more complete views of the right ventricle
than echocardiography.35 CMR is superior to echocardiography in
detecting apical LV thrombi, and patients with large areas of apical
akinesia may benefit from CMR if echocardiography is unclear.81
During the acute phase of Takotsubo syndrome, T2-weighted
CMR shows oedema of the LV myocardium as high signal intensity,
with a diffuse or transmural distribution consistent with the wall
motion abnormality. These features help distinguish Takotsubo
syndrome from myocarditis and acute MI.25–28,82
Typically, LGE is usually absent in Takotsubo syndrome and its
absence is an important distinguishing feature from MI.35 It is
controversial, however, whether minor LGE may be present in
some patients with Takotsubo syndrome during the acute phase
but absent at follow-up CMR. The frequency of LGE depends on
the threshold of signal intensity used to define its presence.83,84
Atypical cases with small areas of persistent apical transmural LGE
have been reported.
If available, CMR should be considered in all patients with
suspected Takotsubo syndrome in the acute phase (within 7 days).
If availability is limited, it should be reserved for borderline and
indeterminate cases (see Diagnostic algorithm). It is also useful
to confirm recovery of ventricular function on follow-up and to
exclude MI or other conditions that can mimic acute Takotsubo
syndrome.
Coronary computed tomography
angiography
In diagnosing Takotsubo syndrome, it is essential to exclude coro-
nary occlusion and significant coronary stenosis. This evaluation
is usually done invasively, as the patient typically presents with
a clinical picture closely resembling that of acute MI. However,
for a delayed presentation (>48 h after chest pain starts and the
patient is pain free at the time of presentation) or for retrospective
evaluation of a patient with the typical history of Takotsubo syn-
drome weeks or months previously, coronary stenoses can also be
excluded by CCTA (Box 4). Acquiring information throughout the
cardiac cycle (spiral or helical acquisition mode) during the acute
phase can also demonstrate the typical pattern of systolic dysfunc-
tion but at the price of a higher radiation exposure.85
Currently there is no evidence for delaying invasive coronary
angiography in patients with ongoing acute chest pain and acute
ECG changes. The ESC guidelines for STEMI or ACS should be
followed until culprit CAD has been excluded.60,86
Radionuclide imaging
The role of radionuclide imaging in the diagnosis and management
of Takotsubo syndrome is undetermined. When CMR is unavail-
able, myocardial perfusion scintigraphy may help exclude infarc-
tion in uncertain cases, and there are reports of normal or mildly
reduced perfusion in the dysfunctional segments, but out of keeping
with the scale of contractile dysfunction.87–89
Iodine-123 meta-iodo-benzyl-guanidine (mIBG) has been used
to image myocardial sympathetic nerve terminal activity and to
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detect adrenal or ectopic phaeochromocytoma, which may be clin-
ically relevant in these patients, although its precise role remains
to be determined. During the acute phase, there is reduced
mIBG in the dysfunctional myocardial segments, consistent with
a regional disturbance of sympathetic neuronal activity.87,89 The
abnormalities can persist for several months, and mIBG scintig-
raphy may have a role in cases without a diagnosis or when the
presentation is remote from an acute episode (Box 4). Ideally,
mIBG imaging should be combined with myocardial perfusion
scintigraphy to exclude infarction; it is unknown whether per-
sisting innervation abnormalities or increased mIBG washout,
reflecting increased sympathetic tone, provides prognostic
information.
Cardiac positron emission tomography using [18F]2-fluoro-
deoxy-glucose has shown abnormal glucose metabolism in the con-
text of normal myocardial perfusion in patients with Takotsubo
syndrome; however, it currently has been used only in a research
context.88,90
Complications and acute prognosis
Takotsubo syndrome has generally been regarded as a relatively
benign disease with rapid recovery of LV function. However,
growing evidence suggests it is a more serious acute cardiac
disorder with a variety of complications in ∼52% of patients
(Table 3).80,91,92
Acute heart failure
Systolic heart failure is the most common complication in the
acute phase of Takotsubo syndrome, occurring in 12–45% of
cases.4,6,7,17,80,92 Independent predictors of acute heart failure
are advanced age, low LVEF at presentation, higher admission
and peak troponin levels, and a physical stressor preceding the
onset of symptoms. Mechanical ventilation, inotropic support, and
intra-aortic balloon pumping have been required in a substantial
number of cases (28, 38, and 17%, respectively).93 In some patients,
pulmonary oedema due to acute LV dysfunction is exacerbated by
mitral regurgitation, LVOTO, or both.
Left ventricular outflow tract obstruction
During the acute phase, a dynamic intraventricular pressure gra-
dient due to mitral valve systolic anterior motion may develop as
a consequence of myocardial stunning of the apical segments and
hypercontraction of the basal LV myocardium. Significant LVOTO
with gradients of 20–140mmHg have been observed in 10–25%
of patients, often accompanied by mitral regurgitation.7,80,94 A
mid-ventricular or LVOTO gradient >25mmHg is considered
haemodynamically significant, and a gradient ≥40mmHg is a
high-risk factor. Abnormal Q waves, hypotension, and cardiogenic
shock are more frequent in these patients. Use of inotropic drugs
or nitrates may exacerbate LVOTO, whereas beta-blockade with
propranolol decreases the gradient.95,96 Normally LVOTO resolves
spontaneously over a few days. ..
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.. Mitral regurgitation
Acute mitral regurgitation is another potentially serious compli-
cation, occurring in 14–25% of patients.97,98 LVEF is lower and
pulmonary artery pressure is higher in patients with significant
regurgitation, who present more often with acute heart failure or
cardiogenic shock. Two independent mechanisms may cause acute
mitral regurgitation: systolic anterior motion of the mitral valve
in association with dynamic LVOTO and apical tethering of the
subvalvular mitral valve apparatus.98,99 In most cases, the mitral
regurgitation decreases as LV function returns to normal, although
recovery may be slower than in patients without acute mitral
regurgitation.
Cardiogenic shock
Cardiogenic shock, primarily due to acute LV dysfunction, occurs
in 4–20% of patients with Takotsubo syndrome and may be exac-
erbated by RV involvement, LVOTO, or acute mitral regurgitation.
Echocardiography may identify the mechanism and help guide ther-
apy. Themortality due to cardiogenic shock in Takotsubo syndrome
is high (17–30%).6,80,91,92,100
Arrhythmias
Arrhythmias are common in patients with Takotsubo syndrome.
New AF has been reported in 5–15% of cases.6,92,101,102 This
arrhythmia further reduces cardiac output and is often asso-
ciated with the onset of heart failure. Ventricular arrhythmias
occur in 4–9% of patients during the acute phase of the
syndrome,6,92,101–103 causing cardiac arrest in 4–6% of cases.
In rare instances, ventricular arrhythmias have been documented
weeks after the first manifestation of Takotsubo syndrome,
when LV function had already normalized. Bradycardia due to
atrioventricular block and asystole has also been described.92
Thrombus formation
Thrombus in the akinetic ventricular apex is observed in 2–8%
of Takotsubo syndrome patients, occasionally resulting in stroke
or arterial embolism.92,104,105 Best visualized by CMR imaging in
early post-contrast acquisition sequences, most thrombi develop
2–5 days after symptom onset, when LV function is still depressed.
However, new thrombus formation and subsequent embolism have
also been described 14 days after symptom onset, when LV systolic
function had already returned to normal. LV thrombi may resolve
with 2 weeks of therapeutic anticoagulation, but a longer course
(usually 3 months) should be considered, and follow-up imaging
is advisable to confirm recovery of apical contractile function.106
Prophylactic anticoagulation in higher risk Takotsubo syndrome
cases has an as yet undetermined role but may be considered (see
Management algorithm for higher risk individuals).
Pericardial effusion
Acute pericarditis with recurrent chest pain, reappearance
of ST-segment elevation, and a small amount of pericardial
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effusion has been observed in some patients during the recov-
ery phase of Takotsubo syndrome.107 CMR imaging early after
admission has detected small pericardial effusions in ∼43% of
patients. Pericardial tamponade requiring pericardiocentesis is rare
(0.05%).108
Ventricular wall rupture
Serious mechanical complications, including ventricular free wall
rupture or interventricular septal perforation, are rare (<1%); they
occur 2–8 days after symptom onset, often with persistent ST
elevation.92,109,110 A high outflow tract gradient may favour rupture
of the LV free wall. One case of RV rupture has been described.
Interventricular septum perforation and acquired ventricular septal
defect can complicate Takotsubo syndrome and may be successfully
treated by surgery.111,112
Right ventricular involvement
Patients with biventricular involvement generally have a more
severe clinical course. RV involvement assessed by echocardiog-
raphy or magnetic resonance imaging has been reported (18–34%
cases) and is associated with older age, lower LVEF, a higher fre-
quency of heart failure, pleural effusion, and a longer hospital
stay.92,113 Rarely, a pressure gradient or an apical thrombus may
be present in the right ventricle.
Mortality during the acute episode
In large studies and registries of Takotsubo syndrome patients,
the in-hospital mortality rate is 2–5%; death is mainly caused
by refractory cardiogenic shock or ventricular fibrillation.80,91,92
In a meta-analysis of 2120 patients in 37 studies, the in-hospital
mortality rate was 4.5%,114 consistent with the 4.2% in-hospital
mortality reported in the large NIS-USA Takotsubo syndrome
cohorts.46,47
Recurrence
Data on recurrence of Takotsubo syndrome are limited by the
relatively short observation period in most studies. Five-year
recurrence rates of 5–22% have been reported, with the second
episode occurring 3 months to 10 years after the first.4,6,22,100
Recurrence of a different anatomical variant has been reported.
Prognosis should be individualized according to the likelihood of
recurrence, the triggering event, and co-existing medical condi-
tions. If a patient has a recurrence, long-term clinical follow-up
should be considered (see Management algorithm).
Long-term prognosis
There are conflicting reports and data regarding the long-term sur-
vival of patients after their initial episode of Takotsubo syndrome.
In two studies, 4-year survival was not different from that of an
age- and gender-matched population.115,116 However, in two other ..
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.. studies, survival at 3 years was significantly lower than that of
a matched general population.100,117 In the prospective SWEDE-
HEART registry, 3-year mortality was similar to that of NSTEMI
and STEMI controls, and these results have recently been con-
firmed by data from the INTER-TAK registry.91,118 Excess mortality
occurs predominantly in the first 4 years after diagnosis and is
related to non-cardiac illnesses such as malignancy.116,119 Data on
the long-term prognosis of patients with Takotsubo syndrome are
limited.
Most patients recover rapidly after the acute episode and have
no symptoms. However, there is increasing evidence that physio-
logical abnormalities persist after resting contractile abnormalities
have returned to normal ‘macroscopically’, and some patients have
persistent cardiac symptoms after the acute episode,116 includ-
ing angina, exertional breathlessness, palpitation, and a tremu-
lous anxiety state, perhaps reflecting heightened sympathetic tone.
Although the coronary arteries are unobstructed and ventricu-
lar function has recovered macroscopically, it is helpful to doc-
ument objective evidence of ongoing cardiac abnormalities to
reassure the patient and to guide treatment. Twenty-four-hour
Holter ECG monitors to identify atrial arrhythmias or inappro-
priate sinus tachycardia (continuous or paroxysmal) may be help-
ful, and 24-h ambulatory blood pressure monitoring may detect
transient and inappropriate hypertensive episodes. Persistent ECG
changes and sometimes other evidence of autonomic disturbance
can provide objective evidence and exclude non-cardiac explana-
tions for ongoing symptoms. The absolute frequency of incomplete
recovery is not well reported, and management of these patients
requires specialist care.
Clinical management (see
Diagnostic algorithm
and Management algorithm)
General considerations
There are no randomized clinical trials to support specific treat-
ment recommendations in Takotsubo syndrome. A key feature of
Takotsubo syndrome is recovery of normal cardiac function. The
major objective of in-hospital treatment should be supportive care
to sustain life and to minimize complications during recovery. In
mild cases, no treatment or a short course of limited medical ther-
apy may be sufficient. In severe cases complicated by progressive
circulatory failure and cardiogenic shock, early mechanical support
should be considered as a ‘bridge-to-recovery’.
Diagnostic and management algorithms have been generated to
help guide clinical decision-making. Risk stratification is essential to
select treatment for patients at greatest risk of complications and
to minimize interventions in patients at low risk where evidence for
treatment is lacking. Given the lack of evidence from randomized
controlled trials, the diagnostic and management algorithms are
based on expert consensus and require validation in prospective
trials. One over-riding consideration in a condition with a high
rate of functional recovery is to respect the fundamental ethical
principle in medicine: primum non nocere (first, do no harm).
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Once the diagnosis is confirmed, it may be helpful to enquire
about previous episodes of unexplained chest pain, and in particular
hospital admissions for chest pain or MI. In some cases, the index
presentation is clearly a recurrence of Takotsubo syndrome (see
‘Prevention of recurrence’).
In diagnosing borderline cases, it may be helpful to review
the history to identify stressful triggers or co-existing medical
conditions that may lead to sudden rises in sympathetic neural
activity and systemic catecholamine levels. If the diagnosis is still
uncertain, cardiac mIBG may be considered to evaluate regional
myocardial sympathetic innervation and tone. It may be necessary
to reserve judgement until follow-up imaging at 3 months confirms
recovery of any RWMA present during the acute phase and clarifies
the presence or absence of permanent LGE by CMR.
Risk stratification
Takotsubo syndrome has been generally regarded as a relatively
benign disease with rapid recovery of LV function. However, a vari-
ety of complications occur in ∼52% of the patients (Table 3).80,91,92
After diagnosis, we recommend that patients with Takotsubo syn-
drome be triaged according to the risk stratification system shown
in Box 4 and the Management algorithm. Higher risk is defined as
the presence of at least one major or two minor risk factors, with
clinical judgement based on their severity.
Given the high risk of complications, where possible all patients
with Takotsubo syndrome should be admitted to a coronary care
unit or high-dependency unit with ECG monitoring for the first
24 h while the investigations and risk stratification are completed.
Patients considered at higher risk of in-hospital mortality should
be monitored in a high-dependency or coronary care unit. Patients
at lower risk may be transferred to wards with lower levels of
monitoring and potentially discharged early. Risk is a continuous
variable and may change as new risk factors are identified. This risk
stratification system is a clinical tool to guide clinicians caring for
patients with Takotsubo syndrome. However, given the absence of
randomized trial evidence, it does not replace clinical judgement.
Validation of the risk stratification algorithm requires a prospective
study, and therefore this proposal is currently based on expect
opinion (level of evidence C).
Management of lower risk cases
of Takotsubo syndrome
In milder cases with an LVEF >45% and no complications, the
patient may be considered for early discharge from hospital.
Before discharge, however, a review of medication is recom-
mended, as many patients will have been started on treatment for
ACS before coronary angiography, and indications for antiplatelet
agents and statins should be reviewed. If LVEF is 35–45% but
the patient is otherwise at lower risk, heart failure medications
including beta-blockers should be considered. In pre-clinical stud-
ies, metoprolol and carvedilol have been beneficial, and these
beta-blockers could be used unless contraindicated (e.g. reversible
airways disease).120,121 Some experts suggest that vasoactive drugs, ..
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.. including ACE inhibitors, should be avoided in patients with normal
cardiac output, as some Takotsubo syndrome patients may have
altered peripheral sympathetic nerve activity associated with low
peripheral vascular resistance.
Takotsubo syndrome patients in the lower risk category should
be followed for 3–6 months after discharge. The follow-up should
include review of medications and cardiac imaging to confirm
recovery of the RWMA.
Management of higher risk cases
of Takotsubo syndrome
General considerations
Takotsubo syndrome cases meeting the criteria for higher risk
should be monitored in a level 2 environment (e.g. coronary
care unit or high-dependency unit) with continuous ECG mon-
itoring and access to resuscitation equipment for at least 72 h
after presentation, when risk of life-threatening complications is
greatest.92 The opinion of a specialist (e.g. cardiologist with a
special interest in heart failure) should be sought where avail-
able. Patients with decreased cardiac output should be consid-
ered for regular echocardiographic monitoring. Cessation of drugs
with sympathomimetic properties is advised (e.g. catecholamines,
beta2-agonists). Beta-blockers may be considered in haemodynam-
ically stable patients and in patients with atrial or ventricular tach-
yarrhythmias. In patients with haemodynamically significant LVOTO
(LVOTO >40mmHg and systolic blood pressure <110mmHg),
treatment with a beta-blocker or selective alpha1-agonist (e.g.
phenylephrine) should be considered. Short-acting intravenous
beta-blockers are preferred acutely, providing no contraindications
exist. If any clinical features suggest phaeochromocytoma, appro-
priate diagnostic studies should be performed before beta-blocker
treatment is started.
In patients with Takotsubo syndrome complicated by cardio-
genic shock, continuous haemodynamic monitoring may help guide
treatment selection. In more severe cases of cardiogenic shock
with progressive end-organ dysfunction, avoidance or withdrawal
of exogenous catecholamines is recommended, as they probably
exacerbate or prolong the acute phase. Treatment options include
mechanical support for acute cardiogenic shock, such as tem-
porary LV assist devices (LVADs) and extracorporeal membrane
oxygenation (ECMO) (see below), or, if those options are not avail-
able, low-dose levosimendan infusion as a catecholamine-sparing
positive inotrope. No evidence currently exists to guide treat-
ment choice in these complex patients, and new trial evidence
is required. Expert consensus suggests that unstable patients
with low cardiac output and cardiogenic shock be managed in
a high-dependency unit (level 2) or intensive care unit (level 3)
and that early LVAD or ECMO support be considered. The
use of inotropes (e.g. dobutamine, norepinephrine, epinephrine,
dopamine, milrinone, and isoproterenol) should be generally
regarded as contraindicated in Takotsubo syndrome,122 as further
activation of catecholamine receptors or their downstream molec-
ular pathways might worsen the clinical status and prognosis of
patients with Takotsubo syndrome and cardiogenic shock.120,123,124
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Mechanical support
Intra-aortic balloon counterpulsation (IABP) has been used to
treat cardiogenic shock due to Takotsubo syndrome. However,
in light of recent neutral data from the IABP-SHOCK II trial and
the fact that IABP may worsen dynamic LVOTO, the consensus
viewpoint is to avoid use of IABP in Takotsubo syndrome patients.
If a patient with primary Takotsubo syndrome is deteriorating
and has a low cardiac output, cardiogenic shock, and progressive
multiorgan failure, specialist advice about ECMO or LVAD as
a bridge-to-recovery is recommended, as there is an excellent
chance that ventricular function will recover fully.125–128 In cases
of secondary Takotsubo syndrome complicated by cardiogenic
shock, the nature, severity, and prognosis of the underlying medical
condition will determine whether mechanical cardiac support is
warranted during the acute phase.
Levosimendan
The role of levosimendan is more controversial, with mixed
expert opinion based on pre-clinical and limited clinical
experience.120,129–133 In the absence of access to emergency
mechanical support, levosimendan may be preferable to other
inotropes such as dobutamine and epinephrine in patients who
have advancing cardiogenic shock and multiorgan failure. Prospec-
tive randomized studies are required to assess the safety and
efficacy of levosimendan in patients with Takotsubo syndrome and
acute heart failure.
Access to all these advanced care options may vary and depend
upon local expertise.
Preventing thrombo-embolism
Takotsubo syndrome may be associated with blood hyperco-
agulability reflecting the vasoconstrictor, platelet activation, or
prothrombotic effects of high catecholamine levels.134 Thrombo-
embolism is a complication in ∼4% of Takotsubo syndrome
patients. Many patients with Takotsubo syndrome will initially
receive antithrombotic treatment for suspected STEMI including
dual antiplatelet therapy (aspirin and P2Y12 receptor antagonists)
and unfractionated or low-molecular-weight heparin. Once MI is
excluded, consensus supports withdrawal of P2Y12 receptor antag-
onists (clopidogrel, prasugrel, and ticagrelor).
Oral anticoagulation is recommended if intraventricular throm-
bus is detected in a patient with Takotsubo syndrome in the
absence of high bleeding risk. Apical thrombus resolution and LV
function recovery should be documented before anticoagulation
is withdrawn. The role of prophylactic anticoagulation remains to
be determined. Therapeutic low-molecular-weight heparin should
be considered in cases with extensive segmental akinesia or atrial
fibrillation.
Follow-up after hospital discharge
Regardless of the severity of their acute episode, all patients should
be offered a follow-up assessment at 3–6 months. It should include ..
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.. repeat cardiac imaging to confirm the resolution of the acute
RWMA and ECG changes observed and to exclude MI by CMRwith
LGE if not performed during the acute admission and in borderline
cases. A review of medication will ensure that any drug therapy
for ACS has been stopped. If LV function has recovered, weaning
from the ACE inhibitor and beta-blocker can be considered in the
absence of other indications.
There is currently no evidence to guide the long-term man-
agement of patients after an episode of Takotsubo syndrome.
Some patients have persistent cardiac symptoms after LVEF and
RWMA have normalized,135 including chest pain, palpitations, and
exertional breathlessness. Further investigations to define the
cause and treatment are advised, as ongoing cardiac abnormalities
(e.g. microvascular perfusion abnormalities, atrial arrhythmias) may
arise months or years after the acute episode.
Given the high risk of complications during the acute phase,
patients with recurrent episodes of Takotsubo syndrome may
warrant long-term follow-up to identify strategies to minimize or
prevent further recurrence (see below).
Preventing recurrence
Prevention of recurrent Takotsubo syndrome has not been demon-
strated in any study. Intuitively, beta-blockers may provide some
protection against future catecholamine surges. However, recur-
rences have been reported in patients taking beta-blockers, and
one meta-analysis found no impact of beta-blockers on the
risk of recurrence, although recurrence was infrequent in both
arms.136,137 Nevertheless, there may be a role for beta-blockers
in selected patients, such as those with evidence of persistently
elevated sympathetic tone, ongoing cardiac symptoms (not clini-
cally recovered), and persistent anxiety and those with recurrent
Takotsubo syndrome.
There is evidence that anxiety states are more frequent in
some patients with Takotsubo syndrome. Given the high fre-
quency of stressful triggers in cases of primary Takotsubo syn-
drome, the psychological response to stress is another potential
therapeutic target. The benefit of psychological counselling and
cognitive behavioural therapy remains to be determined, but they
may have a role in selected cases of recurrence triggered by emo-
tional stressors and in cases of confirmed anxiety disorder.
Late-presenting cases (Box 5)
Some patients have delayed access to medical care or request a
retrospective assessment of ‘troponin-positive chest pain episodes
with normal coronary arteries’ lacking a diagnosis. A careful review
of the history and risk factor profile may alter the probability that
the episode in question was an acute Takotsubo syndrome (Box 5).
Review of ECGs and cardiac biomarkers, if available, may aid
detection of the classical features that discriminate Takotsubo syn-
drome from ACS. Cardiac imaging, including echocardiography and
CMR with LGE, helps exclude MI and other possible conditions.
The role of cardiac mIBG is exploratory and may help demon-
strate regional abnormalities of cardiac sympathetic innervation in
© 2015 The Authors
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Box 5 Heart Failure Association
management strategy for
late-presenting Takotsubo
syndrome cases
Late or retrospective review:
Review history
Review risk factors
Review ECGs
Review cardiac biomarker profile (serum natriuretic peptides
and troponin) from acute episode
Consider:
Cardiac MRI + LGE (exclude MI, HCM)
CCTA (exclude obstructive CAD)
Cardiac mIBG
CCTA, coronary computed tomography angiography; HCM,
hypertrophic cardiomyopathy; LGE, late gadolinium enhance-
ment; MI, myocardial infarction; mIBG, iodine-123 meta-iodo-
benzyl-guanidine; MRI, magnetic resonance imaging.
a classical anatomical pattern and in the absence of infarction or
alternative explanation.
Conclusion and future directions
Takotsubo syndrome is a fascinating acute heart failure syndrome,
now increasingly recognized by the medical community. Many facets
of this condition are incompletely understood or characterized,
and current knowledge to guide optimal clinical management is
limited. However, the increasing incidence and the high frequency
of complications during the acute phase underpin the need to
improve care pathways for patients with Takotsubo syndrome.
To date, clinical reports are mostly based on relatively small
cohorts and case series. Therefore, the recommendations of
this Position Statement reflect the consensus of expert opinion
(level of evidence C). Randomized controlled trials are needed to
identify optimal diagnostic and management strategies for Takot-
subo syndrome. The potential for national and international reg-
istries to collect larger numbers of patients prospectively should
aid understanding of the epidemiology and natural history. Takot-
subo syndrome networks may also provide the infrastructure
for research studies and, in particular, given the lack of current
evidence-based treatments, for assessing novel therapeutic strate-
gies. Individual hospitals may see no more than ∼5–30 cases per
annum, and broader networks are required to collect larger num-
bers of patients. Several countries have started to co-ordinate data
collection in regional or national registries, and one international
registry, the InterTAK registry (NCT01947621), has been launched
to gather 10-year follow-up data on a large cohort of prospectively
enrolled patients with confirmed Takotsubo syndrome. ..
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.. This is the first Position Statement from the ESC Heart Failure
Association for this acute heart failure syndrome. It will be
updated when further advances in the understanding and manage-
ment of Takotsubo syndrome are available, and particularly when
results from randomized controlled trials are available to provide
a stronger evidence base for clinical decision-making.
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